Curevac N.V. (CVAC)

$5.05 -0.07 (-1.37%)
Market Cap 1.13B
Revenue (ttm) 579.12M
Net Income (ttm) 175.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 30.30%
Debt to Equity Ratio 0.00
Volume 644,400
Avg Vol 995,690
Day's Range N/A - N/A
Shares Out 224.34M
Stochastic %K 0%
Beta 1.77
Analysts Hold
Price Target $5.32

Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytopl...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 7071 9883 0
Address:
Friedrich-Miescher-Strasse 15, Tübingen, Germany
Arthur715
Arthur715 Dec. 12 at 1:26 AM
$CVAC
0 · Reply
Arthur715
Arthur715 Dec. 12 at 1:21 AM
$CVAC when reversal
0 · Reply
taxplanr
taxplanr Dec. 11 at 2:45 PM
$BNTX maybe it was just a bad time to take on more overhead and operational losses with $CVAC 🤔
0 · Reply
PixPirate
PixPirate Dec. 6 at 1:52 PM
$CVAC
0 · Reply
PixPirate
PixPirate Dec. 6 at 1:50 PM
$CVAC not even moving a littlw just frozen
0 · Reply
PixPirate
PixPirate Dec. 6 at 1:50 PM
$CVAC 6k watchers
0 · Reply
PixPirate
PixPirate Dec. 6 at 1:50 PM
$CVAC
0 · Reply
taxplanr
taxplanr Dec. 3 at 4:09 PM
$BNTX $CVAC when does that ACIP meeting start?
0 · Reply
taxplanr
taxplanr Dec. 2 at 3:02 PM
$BNTX $CVAC game of chicken with ACIP board meeting GLTA
0 · Reply
taxplanr
taxplanr Dec. 2 at 3:32 AM
$BNTX $MRNA $PFE just another sharp shooter for the end of the week firing squad $CVAC https://justthenews.com/politics-policy/health/rfk-jr-appoints-former-acip-chairman-martin-kulldorff-senior-hhs-post?utm_source=mux&utm_medium=social-media&utm_campaign=social-media-autopost
0 · Reply
Latest News on CVAC
BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 10 days ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

BNTX

CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript

Nov 28, 2025, 3:33 AM EST - 15 days ago

CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript

CureVac Announces Voting Results of Extraordinary General Meeting

Nov 25, 2025, 7:05 PM EST - 18 days ago

CureVac Announces Voting Results of Extraordinary General Meeting

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

Nov 24, 2025, 7:30 AM EST - 19 days ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

CureVac: The Hidden Value Of The mRNA Wallet

Oct 1, 2025, 5:26 AM EDT - 2 months ago

CureVac: The Hidden Value Of The mRNA Wallet

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

Aug 15, 2025, 7:50 AM EDT - 4 months ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7, 2025, 9:00 PM EDT - 4 months ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

BNTX PFE

CureVac Announces Voting Results of General Meeting

Jun 24, 2025, 4:35 PM EDT - 6 months ago

CureVac Announces Voting Results of General Meeting

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

Jun 12, 2025, 12:05 PM EDT - 6 months ago

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

BA ORCL

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

Jun 12, 2025, 11:07 AM EDT - 6 months ago

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BNTX

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

Jun 12, 2025, 7:11 AM EDT - 6 months ago

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

BNTX

BioNTech to acquire CureVac in $1.25 billion all-stock deal

Jun 12, 2025, 7:03 AM EDT - 6 months ago

BioNTech to acquire CureVac in $1.25 billion all-stock deal

BNTX

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

May 20, 2025, 7:15 AM EDT - 7 months ago

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

May 15, 2025, 4:45 PM EDT - 7 months ago

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript

Apr 10, 2025, 12:59 PM EDT - 8 months ago

CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Apr 10, 2025, 7:30 AM EDT - 8 months ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

Apr 8, 2025, 7:25 AM EDT - 8 months ago

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Apr 7, 2025, 7:15 AM EDT - 8 months ago

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit

Mar 28, 2025, 12:45 PM EDT - 9 months ago

CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit

BNTX

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

Mar 28, 2025, 8:58 AM EDT - 9 months ago

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

European Patent Office declares CureVac mRNA patent valid

Mar 27, 2025, 6:22 PM EDT - 9 months ago

European Patent Office declares CureVac mRNA patent valid

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

Mar 27, 2025, 4:30 PM EDT - 9 months ago

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

Feb 18, 2025, 7:15 AM EST - 10 months ago

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

Jan 8, 2025, 4:55 PM EST - 1 year ago

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 3:08 PM EST - 1 year ago

CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

Nov 12, 2024, 7:20 AM EST - 1 year ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

Nov 4, 2024, 7:20 AM EST - 1 year ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Present at the 12th International mRNA Health Conference

Nov 4, 2024, 7:15 AM EST - 1 year ago

CureVac to Present at the 12th International mRNA Health Conference

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 28, 2024, 8:10 AM EDT - 1 year ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

Oct 8, 2024, 5:50 AM EDT - 1 year ago

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

BNTX PFE

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Sep 13, 2024, 8:15 AM EDT - 1 year ago

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Sep 12, 2024, 7:15 AM EDT - 1 year ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Sep 9, 2024, 7:15 AM EDT - 1 year ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

Aug 15, 2024, 7:30 AM EDT - 1 year ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

Aug 15, 2024, 7:20 AM EDT - 1 year ago

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

Aug 15, 2024, 7:15 AM EDT - 1 year ago

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Jul 11, 2024, 7:15 AM EDT - 1 year ago

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

Jul 3, 2024, 10:18 AM EDT - 1 year ago

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

GSK

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

Jul 3, 2024, 7:53 AM EDT - 1 year ago

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

GSK

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

Jul 3, 2024, 2:40 AM EDT - 1 year ago

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Jul 3, 2024, 2:40 AM EDT - 1 year ago

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

GSK buys full rights to make COVID, influenza vaccines from CureVac

Jul 3, 2024, 2:26 AM EDT - 1 year ago

GSK buys full rights to make COVID, influenza vaccines from CureVac

GSK

CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript

Apr 24, 2024, 3:12 PM EDT - 1 year ago

CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Apr 24, 2024, 7:30 AM EDT - 1 year ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Apr 24, 2024, 7:20 AM EDT - 1 year ago

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Apr 24, 2024, 7:20 AM EDT - 1 year ago

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Apr 18, 2024, 7:15 AM EDT - 1 year ago

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Arthur715
Arthur715 Dec. 12 at 1:26 AM
$CVAC
0 · Reply
Arthur715
Arthur715 Dec. 12 at 1:21 AM
$CVAC when reversal
0 · Reply
taxplanr
taxplanr Dec. 11 at 2:45 PM
$BNTX maybe it was just a bad time to take on more overhead and operational losses with $CVAC 🤔
0 · Reply
PixPirate
PixPirate Dec. 6 at 1:52 PM
$CVAC
0 · Reply
PixPirate
PixPirate Dec. 6 at 1:50 PM
$CVAC not even moving a littlw just frozen
0 · Reply
PixPirate
PixPirate Dec. 6 at 1:50 PM
$CVAC 6k watchers
0 · Reply
PixPirate
PixPirate Dec. 6 at 1:50 PM
$CVAC
0 · Reply
taxplanr
taxplanr Dec. 3 at 4:09 PM
$BNTX $CVAC when does that ACIP meeting start?
0 · Reply
taxplanr
taxplanr Dec. 2 at 3:02 PM
$BNTX $CVAC game of chicken with ACIP board meeting GLTA
0 · Reply
taxplanr
taxplanr Dec. 2 at 3:32 AM
$BNTX $MRNA $PFE just another sharp shooter for the end of the week firing squad $CVAC https://justthenews.com/politics-policy/health/rfk-jr-appoints-former-acip-chairman-martin-kulldorff-senior-hhs-post?utm_source=mux&utm_medium=social-media&utm_campaign=social-media-autopost
0 · Reply
taxplanr
taxplanr Dec. 1 at 3:07 PM
$CVAC what a bummer
1 · Reply
taxplanr
taxplanr Dec. 1 at 2:26 PM
I tried to warn $CVAC shareholders If you still think malignantRNA is viable get used to the dumping by Biontech insiders
0 · Reply
OnlyFibs
OnlyFibs Dec. 1 at 12:44 AM
$CVAC is signaling a powerful move: price is BULLISH over the 50/200 SMA, and the unusual volume confirms strong institutional interest. Key Levels: Bulls (Target): Break above $5.72 (52-week high) opens the door for a major breakout. Bears (Risk Line): A close below $5.30 (200 SMA support) invalidates the bullish trend. Volume is the conviction! Watch for that resistance flip. 📈 #Biotech #Stocks #CVAC #hovdid
0 · Reply
taxplanr
taxplanr Nov. 26 at 3:39 PM
$BNTX Dec 4 approaches ... get your hedges in $CVAC while triple digits last https://finviz.com/news/239392/biontech-shares-progress-on-exchange-offer-for-curevac-shares-and-highlights-december-3-2025-at-9-00-am-eastern-time-expiration
0 · Reply
ACCESSWIRE
ACCESSWIRE Nov. 26 at 2:24 AM
CureVac ($CVAC) Announces Voting Results of Extraordinary General Meeting . https://tinyurl.com/ANWire
0 · Reply
taxplanr
taxplanr Nov. 25 at 7:33 PM
Last chance for $CVAC shareholders to dump $BNTX
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 20 at 5:30 PM
$CVAC need to address this post RS beloved here
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 5 at 6:25 PM
$CTRE $CTSH $CTXR $CURE $CVAC
0 · Reply
taxplanr
taxplanr Nov. 3 at 2:51 PM
$BNTX Lower sales volumes for their only gene therapy on the market No mention of any phase 3 trials No mention of how they can support $CVAC losses and trials
0 · Reply
JaredSotken
JaredSotken Oct. 24 at 8:05 PM
$CVAC Why are you even tagging me on this ticker that I am not in? Trying to justify your stupidity on $BNTX ? 😅 @taxplanr
0 · Reply
Andrewfritzen01
Andrewfritzen01 Oct. 24 at 6:57 PM
$BNTX $CVAC $PFE so… using all debt to purchase. Not a great sign of the times.
1 · Reply
Jnbond7
Jnbond7 Oct. 24 at 5:57 PM
$CVAC OMG! $CVAC finally pulled it off. $CVAC clearly stepped on its own d%ck concerning the covid-19 vaccine, but like the little engine that could, it managed to pull off a miracle.
0 · Reply